Shortly after the beginning of 2023, the market reported that Hengrui Pharmaceutical, the "first brother of medicine", announced internally that Jiang Ningjun, who had been one of the founders of CStone Pharmaceutical, was appointed as the deputy general manager and chief strategy officer of Hengrui Pharmaceutical, and he was responsible for the company's clinical research and business development
.
This news has attracted great attention
from the industry.
According to public information, Jiang Ningjun not only has six years of working experience in CStone Pharmaceuticals, but also served as the vice president of Sanofi's China R&D center, fully responsible for Sanofi's new drug research and development and clinical research
in China.
In recent years, with the normalization of centralized procurement, medical insurance fee control, consistency evaluation and other medical reform policies, the changes in the pharmaceutical market have intensified, the pace of innovation and transformation of pharmaceutical companies has accelerated, and the executives of related companies have also changed blood
.
Taking Hengrui as an example, the pharmaceutical company has been accompanied by many changes in senior management in the process of transformation, for example, not long ago, on December 4, 2022, Hengrui issued an announcement that Zhang Xiaojing, deputy general manager and chief medical officer (oncology) of the company, resigned
due to personal reasons.
In addition, in 2022, Hengrui also adjusted the clinical R&D team, including the internal announcement of the appointment of Dr.
Shi Wei, Dr.
Zhu Xiaoyu and Dr.
Wang Linna as the deputy general managers of the clinical R&D department, respectively serving as the chief medical officer (CMO) of clinical research of
chest, breast tumor, and digestive tract tumor.
In addition to Hengrui Pharmaceutical, the recent departure information of some senior executives of local pharmaceutical companies and the end of 2022 has also revealed the internal changes
of major pharmaceutical companies.
For example, on January 10, 2022, Dongea Ejiao issued an announcement that Han Yuewei, chairman of the company, applied to resign as chairman of the company due to changes in work content, and the former president Gao Dengfeng took over as chairman, and Cheng Jie became the new president
of the company.
A month ago, Dongea Jiao issued an announcement that Liu Yanfeng and Ren Ruzhuo applied to resign as vice presidents of the company due to job changes
.
In this regard, some market participants believe that the senior management of Dongea Ejiao is constantly changing, or that the major shareholder China Resources is part of the management adjustment of
its company.
On December 29, 2022, Guangyuyuan issued an announcement that Mr.
Wang Peiyi and Mr.
Li Zhong resigned as vice presidents of the company due to retirement age and personal reasons, respectively, and Mr.
Wang Peiyi and Mr.
Li Zhong will no longer hold any position
in the company after their resignation.
Earlier, in the first half of 2022, Guangyuyuan and vice presidents such as Fu Shuhong, Zhang Yi, and Liang Peng announced their resignations
one after another.
At the same time, Zhang Bin of Shanxi Guangyuyuan, a subsidiary of Guangyuyuan, announced his resignation as chairman of Shanxi Guangyuyuan, which changed its business scope at that time, and after the change, added pharmaceutical Internet information services, and at the same time removed the production, processing and sales
of traditional Chinese medicine pieces.
On December 5, 2022, blood product company Tiantan Biotechnology announced that chairman Yang Xiaoming resigned due to job changes and was replaced by Yang Huichuan
.
According to the 2021 annual report of Tiantan Biotechnology, Yang Xiaoming is 60 years old this year, and the original term of office of his chairman should end
on June 22, 2023.
.
.
.
.
.
.
In addition to local pharmaceutical companies, multinational pharmaceutical companies have also made frequent moves at the end of 2022, such as Zhuang Wenyan, executive vice president of Fresenius Kabi, who ended his current position on January 1, 2023 due to retirement, Dong Bowen of Boehringer Ingelheim Greater China will become president and CEO of Boehringer Ingelheim Greater China on March 1, 2023, and Bill Anderson, CEO of Roche's pharmaceutical business, also announced his departure
to seek opportunities outside Roche.
Some industry insiders pointed out that due to the current demand for talents with work experience in domestic pharmaceutical companies and multinational pharmaceutical companies, the whereabouts of such talents have also attracted much attention from the industry, and overall, in 2023, it is worth waiting to see how the pharmaceutical industry will develop after the change of senior management!
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
